CLDX Celldex Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$35.66

Period return

+8.81 (+32.81%)

Volume

1.2M

2026-07-21O $35.58 H $35.99 L $34.56 C $35.66MA5 $36.03MA20 $36.88MA60 $33.36MA120 $31.21

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 13.LowBUY2 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 05. 08.LowBUY2 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 04. 20.MediumBUY3 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 03. 03.LowHOLD5 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2026. 02. 26.LowBUY5 months ago
Stifel: Buy
US analyst rating / recommendation change.
2025. 12. 18.LowSELL7 months ago
Barclays: Underweight
US analyst rating / recommendation change.
2025. 11. 12.LowSELL8 months ago
Barclays: Underweight
US analyst rating / recommendation change.
2025. 10. 21.MediumBUY9 months ago
Mizuho: Outperform
US analyst rating / recommendation change.
2025. 10. 13.MediumSELL9 months ago
Barclays: Underweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $58.43 · 14 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Sector: Healthcare
Industry: Biotechnology
HQ: Hampton, NJ, United States
Fiscal year end: —
Employees: 198
IPO date: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-1.06	—	—	$858.9K	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.81	—	—	$695K	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-1.74	—	—	$5.85M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-1.1	—	—	$2.65M	Reported

Celldex Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 05. 08.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 04. 20.	Barclays	—	Upgrade	Underweight → Overweight	—	Barclays: Underweight → Overweight
2026. 03. 03.	Goldman Sachs	—	Maintain	Neutral → Neutral	—	Goldman Sachs: Neutral
2026. 02. 26.	Stifel	—	Maintain	Buy → Buy	—	Stifel: Buy
2025. 12. 18.	Barclays	—	Maintain	Underweight → Underweight	—	Barclays: Underweight